The U.S. Food and Drug Administration accepted Jazz Pharmaceuticals’ supplemental Biologics License Application for Ziihera (zanidatamab‑hrii) as a first‑line therapy for HER2‑positive gastric, gastroesophageal junction, or gastroesophageal adenocarcinoma. The acceptance grants the drug priority review status and places it under the FDA’s Real‑Time Oncology Review program, with a PDUFA target action date of August 25 2026.
The decision follows the HERIZON‑GEA‑01 Phase 3 trial, which compared zanidatamab plus standard chemotherapy, with or without the PD‑1 inhibitor Tevimbra®, to chemotherapy alone. The study reported a median progression‑free survival of 12.4 months versus 8.1 months for the control arm, and an overall survival benefit that, while not yet statistically significant in the interim analysis, is expected to reach significance in the final analysis. These results are described as “practice changing” by experts and suggest zanidatamab could become the HER2‑targeted agent of choice in this setting.
The first‑line HER2‑positive gastroesophageal adenocarcinoma market is sizable, with roughly 20 % of patients exhibiting HER2 overexpression. Analysts estimate that Ziihera could generate peak annual sales exceeding $2 billion in the United States and Canada, making the GEA indication the primary driver of Jazz’s oncology portfolio growth.
Current first‑line therapy for HER2‑positive GEA is trastuzumab plus chemotherapy. Ziihera’s data represent the first immuno‑oncology combination to demonstrate efficacy across both PD‑L1–positive and PD‑L1–negative tumors, potentially positioning it as the new standard of care and giving Jazz a competitive edge over existing options.
Rob Iannone, M.D., M.S.C.E., executive vice president, global head of R&D and chief medical officer of Jazz, said, “The HERIZON‑GEA‑01 trial results are practice changing, supporting the potential of zanidatamab as the HER2‑targeted agent‑of‑choice in HER2+ first‑line locally advanced or metastatic GEA. Importantly, the results demonstrated adding tislelizumab to zanidatamab plus chemotherapy further enhanced clinical benefit and marked the first immuno‑oncology combination to show efficacy across both PD‑L1–positive and PD‑L1–negative tumors in this clinical setting.”
Jazz’s broader financial picture underscores the strategic importance of this filing. The company reported total revenues of $4.3 billion in 2025, a 5 % year‑over‑year increase, and is guiding 2026 total revenue at $4.25 billion to $4.5 billion. Ziihera’s net product sales in biliary tract cancer reached $25 million in 2025, with $9 million in Q4 2025, following its December 2024 launch. The new GEA indication could therefore add a multi‑billion‑dollar revenue stream to an already robust oncology platform.
The FDA’s acceptance signals a clear regulatory path and positions Jazz to potentially capture a significant share of a high‑need market, reinforcing its strategy to expand its oncology footprint and deliver substantial shareholder value.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.